| Drug Name |
Guanfacine |
| Drug ID |
BADD_D01046 |
| Description |
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841]
Guanfacine was granted FDA approval on 27 October 1986.[L11274] |
| Indications and Usage |
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277] |
| Marketing Status |
approved; investigational |
| ATC Code |
C02AC02 |
| DrugBank ID |
DB01018
|
| KEGG ID |
D08031
|
| MeSH ID |
D016316
|
| PubChem ID |
3519
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
0591-0444; 0591-0453; 27241-243; 42291-326; 60505-3928; 62135-728; 70436-040; 72162-2029; 16714-191; 16714-192; 42806-296; 60429-960; 70436-042; 71205-946; 0228-2855; 53746-711; 60505-3929; 60505-3930; 63629-1102; 63629-8203; 70518-1369; 71205-945; 63304-927; 65162-713; 70436-039; 70518-2771; 24658-730; 24979-198; 0228-2851; 63629-1105; 16714-190; 16714-193; 24979-538; 60429-961; 62135-727; 63629-8161; 70518-1371; 71205-947; 24979-199; 24979-536; 50268-374; 63304-926; 24658-731; 42806-048; 53746-713; 54092-515; 60429-962; 60429-963; 60505-3927; 63629-1103; 65162-711; 70436-041; 71335-9750; 72162-2030; 42291-327; 0228-2850; 0228-2853; 54092-517; 63187-302; 63304-924; 63304-925; 71205-944; 24979-534; 27241-242; 42291-325; 50090-5991; 54092-519; 63629-1104; 68094-065; 70518-0793; 0904-7140; 24979-533; 42291-324; 50090-6073; 50090-6493; 54092-513 |
| UNII |
30OMY4G3MK
|
| Synonyms |
Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic |
